ELDN · Eledon Pharmaceuticals, Inc. · Suppliers & Customers
$2.62
+0.00 (+0.00%)
At close · Nov 3
Return incl. dividend (before tax)
Q1 2023 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's current operating plan, the Company expects that, within the next twelve months, its existing cash, cash equivalents, short-term investments and other available resources will not be sufficient to fund its planned operations and satisfy its obligations as they become due unless it obtains additional financing. Based on these conditions and events that are known and reasonably knowable as of the date these condensed consolidated financial statements are issued, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Although management intends to obtain additional financing through the sources described above, these plans are subject to market conditions and other factors outside the Company's control. Accordingly, management has concluded that its plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$212.90M
Shares
81.26M
Volume · Nov 3
403.17K
Avg daily vol (3M)
913.96K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Supply Chain
Customers, suppliers, competitors and partners, private companies included: the ones ELDN names, and the companies that name ELDN.
Read supply chains in your AI or your code through MCP and the API →
Pro
See who ELDN sells to, buys from and competes with
- 0 suppliers
- 0 customers
- 20 competitors
Pro names each company, links it to its own page, shows any revenue share the filing states, and quotes the sentence it comes from.
Key facts
CIK
1404281
CUSIP
28617K101
13F (30d)
45 filings
44 filers
Visit website
Investor relations